Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,456,145
  • Shares Outstanding, K 207,133
  • Annual Sales, $ 331,410 K
  • Annual Income, $ -226,540 K
  • EBIT $ -41 M
  • EBITDA $ -49 M
  • 60-Month Beta 1.89
  • Price/Sales 4.66
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 48.04% ( -3.38%)
  • Historical Volatility 66.55%
  • IV Percentile 7%
  • IV Rank 19.83%
  • IV High 132.06% on 02/13/24
  • IV Low 27.27% on 10/11/24
  • Put/Call Vol Ratio 0.81
  • Today's Volume 851
  • Volume Avg (30-Day) 963
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 46,737
  • Open Int (30-Day) 43,619

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.10
  • Number of Estimates 5
  • High Estimate -0.01
  • Low Estimate -0.19
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +64.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.84 +2.85%
on 11/04/24
8.44 -16.59%
on 11/01/24
-0.58 (-7.61%)
since 10/18/24
3-Month
6.84 +2.85%
on 11/04/24
8.88 -20.72%
on 09/03/24
-0.60 (-7.85%)
since 08/16/24
52-Week
4.03 +74.69%
on 04/25/24
8.88 -20.72%
on 09/03/24
+1.69 (+31.59%)
since 11/17/23

Most Recent Stories

More News
BioCryst Launches ORLADEYO® (berotralstat) in Ireland

BCRX : 7.04 (+0.14%)
BioCryst to Present at Upcoming Investor Conferences

BCRX : 7.04 (+0.14%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRX : 7.04 (+0.14%)
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript

BCRX earnings call for the period ending September 30, 2024.

BCRX : 7.04 (+0.14%)
BioCryst: Q3 Earnings Snapshot

BioCryst: Q3 Earnings Snapshot

BCRX : 7.04 (+0.14%)
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

BCRX : 7.04 (+0.14%)
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

BCRX : 7.04 (+0.14%)
BioCryst to Report Third Quarter 2024 Financial Results on November 4

BCRX : 7.04 (+0.14%)
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

BCRX : 7.04 (+0.14%)
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

BCRX : 7.04 (+0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

3rd Resistance Point 7.98
2nd Resistance Point 7.75
1st Resistance Point 7.39
Last Price 7.04
1st Support Level 6.80
2nd Support Level 6.57
3rd Support Level 6.21

See More

52-Week High 8.88
Last Price 7.04
Fibonacci 61.8% 7.03
Fibonacci 50% 6.45
Fibonacci 38.2% 5.88
52-Week Low 4.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar